Abiopharma

🔍 Glick Gary D (Executive)

Company: Odyssey Therapeutics, Inc. (ODTX)

Report Date: 2026-05-07

Detailed Transactions and Holdings:

• Acquired 27,386 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | shares_owned_after: 415,973.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 10,291 shares of Series C Convertible Preferred Stock (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1, F3
• Sold 17,095 shares of Series D Convertible Preferred Stock (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F2, F2, F2, F2, F3
• Acquired 884,450 shares of Stock Option (Right to Buy) at $18.0 per share (Derivative)
  Date: 2026-05-07 | Code: A | Expires: 2036-05-06 | equity_swap_involved: false | shares_owned_after: 884,450.00 | transaction_form_type: 4 | Footnotes: F4

Footnotes:

• F1: The Series C Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration.
• F2: The Series D Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration.
• F3: Gives effect to the 1-for-9.7170 reverse stock split effected prior to the closing of the Issuer's initial public offering.
• F4: Option vests in forty-eight (48) equal monthly installments, with the first installment scheduled to vest on June 7, 2026, subject to the Reporting Person's continued service on each such vesting date.
• REMARKS: President and Chief Executive Officer